Relationship Extraction for Adverse Drug Events in Clinical Notes Using Large Language Models
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Adverse drug events (ADEs) are a critical indicator of patient safety but are often documented only in free-text clinical notes. The potential of recent advances in natural language processing (NLP), particularly generative large language models (LLMs), to identify ADEs remains understudied. This study aimed to compare the performance of multiple LLMs in identifying ADE-Drug relationships in inpatient and ambulatory clinical notes.
Methods
We used clinical notes from the 2018 National NLP Clinical Challenge (n2c2) ADE dataset (inpatient; n=505) and from outpatient encounters (n=2,555) between October 1, 2018, and December 31, 2019, at a large academic medical center based in New England. Notes were pre-processed into snippets for model input. Evaluated Models included: GPT-4o, GPT-4o-mini, LLAMA 3.3-70B and their instruction fine-tuned variants (including low-rank adapters for LLAMA). Performance was assessed using both strict and relaxed evaluations (precision, recall, and F1) for all models, followed by manual evaluation (exact semantic match, partial match, missing ADE, drug mention only, not a drug, or wrong) of the two best-performing models.
Results
GPT-4o and GPT-4o-mini were the top-performing models among those evaluated. GPT-4o consistently outperformed GPT-4o-mini in ADE extraction across both datasets, with higher F1-scores (0.524 vs. 0.381) and a more balanced precision-recall profile. Both models captured ADEs effectively in explicit and complex clinical contexts, although limitations included misclassification of pre-existing allergies and occasional conflation of therapeutic indications with adverse effects. GPT-4o achieved higher exact match coverage and fewer errors across clinical notes, indicating more reliable performance in both inpatient and ambulatory settings.
Conclusion
This work establishes a foundation for integrating LLM methods into real-world drug safety surveillance, with direct implications for improving patient safety.
